Genelux Corporation has announced a proposed underwritten public offering of its common stock. The company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares. Lucid Capital Markets is the sole book-running manager for the offering. The offering is being made pursuant to an effective shelf registration statement filed with the SEC. Genelux is a biopharmaceutical company focused on developing oncolytic immunotherapies for solid tumors and is currently involved in multiple clinical trials for its product Olvi-Vec. The offering is subject to market conditions and customary closing conditions.

Investors interested in Genelux Corporation should take note of the proposed underwritten public offering of its common stock. The company is focusing on developing oncolytic immunotherapies for difficult-to-treat solid tumor types. Genelux’s product Olvi-Vec is currently being evaluated in U.S.-based clinical trials for ovarian and lung cancer. The offering is subject to market conditions and the satisfaction of customary closing conditions. Interested parties can obtain more information about the offering by visiting the SEC’s website or contacting Lucid Capital Markets directly.

Read more at GlobeNewswire: Genelux Corporation Announces Proposed Public Offering of